
OMB APPROVAL

OMB Number: 3235-0145
Expires: December 31, 1997
Estimated average burden
hours per response. . .14.90

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT) *

Alexion Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock (\$.0001 par value)

(Title of Class of Securities)

015351109

(CUSIP Number)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 015351109

13G

PAGE 2 OF 17

1 NAME OF REPORTING PERSON BIOTECHNOLOGY INVESTMENT GROUP, LLC ("BIO")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

891,898

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

[]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

00

*SEE INSTRUCTIONS BEFORE FILLING OUT!

3

CUSIP NO. 015351109

13G

PAGE 3 OF 17

1 NAME OF REPORTING PERSON EDWARD BLECH TRUST ("EBT")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

New York

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY

6 SHARED VOTING POWER

891,898

EACH
REPORTING
PERSON
WITH

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

OO

*SEE INSTRUCTIONS BEFORE FILLING OUT!

4

CUSIP NO. 015351109

13G

PAGE 4 OF 17

1 NAME OF REPORTING PERSON COLLINSON HOWE VENTURE PARTNERS, INC.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

891,898

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT!

5

CUSIP NO. 015351109

13G

PAGE 5 OF 17

1 NAME OF REPORTING PERSON SCHRODERS INCORPORATED ("SI")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []

(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

891,898

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT!

6

1 NAME OF REPORTING PERSON JEFFREY J. COLLINSON ("JJC")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

	5	SOLE VOTING POWER	
		7,131	
NUMBER OF			
SHARES	6	SHARED VOTING POWER	
BENEFICIALLY		899,029	
OWNED BY			
EACH	7	SOLE DISPOSITIVE POWER	
REPORTING		7,131	
PERSON			
WITH	8	SHARED DISPOSITIVE POWER	
		899,029	

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
899,029

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
12.2%

12 TYPE OF REPORTING PERSON*
IN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

7

1 NAME OF REPORTING PERSON SCHRODER VENTURES U.S. TRUST ("SVUST")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Bermuda

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

891,898

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

OO

*SEE INSTRUCTIONS BEFORE FILLING OUT!

8

CUSIP NO. 015351109

13G

PAGE 8 OF 17

1 NAME OF REPORTING PERSON SCHRODER VENTURES LIMITED PARTNERSHIP ("SVLP")
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON N/A

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

5 SOLE VOTING POWER

-0-

NUMBER OF
SHARES

6 SHARED VOTING POWER

BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

891,898

7 SOLE DISPOSITIVE POWER

-0-

8 SHARED DISPOSITIVE POWER

891,898

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

891,898

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.1%

12 TYPE OF REPORTING PERSON*

PN

*SEE INSTRUCTIONS BEFORE FILLING OUT!

9

CUSIP NO. 015351109

13G

PAGE 9 OF 17

ITEM 1(a). NAME OF ISSUER: Alexion Pharmaceuticals, Inc.

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

25 Science Park
New Haven, CT 06511

ITEM 2. NAMES, ADDRESSES AND CITIZENSHIP OF PERSONS FILING:

I. For Reporting Person

BIOTECHNOLOGY INVESTMENT GROUP, L.L.C.:

- a) Biotechnology Investment Group, L.L.C.
- b) c/o Collinson Howe Venture Partners, Inc.
1055 Washington Boulevard
Stamford, CT 06901
- c) Place of organization -- Delaware

II. REGARDING REPORTING PERSON EDWARD BLECH TRUST:

- a) Edward Blech Trust
- b) 418 Avenue I
Brooklyn, NY 11231
- c) Trusted created under laws of New York

REGARDING REPORTING PERSON COLLINSON HOWE VENTURE PARTNERS, INC.

- a) Collinson Howe Venture Partners, Inc.

- b) 1055 Washington Boulevard
Stamford, CT 06901
- c) Place of Organization - Delaware

REGARDING REPORTING PERSON:

- a) Schroders Incorporated
- b) 787 Seventh Avenue, 29th Floor
New York, NY 10019
- c) Place of Organization -- Delaware

10

```

-----
CUSIP NO. 015351109          13G          PAGE 10 OF 17
-----

```

REGARDING REPORTING PERSON JEFFREY J. COLLINSON:

- a) Jeffrey J. Collinson
- b) 1055 Washington Boulevard,
Stamford, CT 06901
- c) Citizenship - United States

REGARDING REPORTING PERSON SCHRODER VENTURES US TRUST:

- a) Schroder Ventures U.S. Trust
- b) c/o Schroder Venture Managers Limited
22 Church Street
Hamilton HM 11, Bermuda
- c) SVUST is a closed-end unit trust created under the laws of Bermuda

REGARDING REPORTING PERSON SCHRODER VENTURES LIMITED PARTNERSHIP:

- a) Schroder Ventures Limited Partnership
- b) c/o Schroder Ventures Management L.P.
787 Seventh Avenue
29th Floor
New York, NY 10019
- c) Place of organization -- Delaware

ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Stock

ITEM 2(e). CUSIP NUMBER: N/A

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES

13D-1(b), or 13D-2(b), CHECK WHETHER THE PERSON FILING IS A:

- (a) Broker or Dealer registered under Section 15 of the Act,
- (b) Bank as defined in Section 3(a)(6) of the Act,
- (c) Insurance Company as defined in Section 3(a)(19) of the Act,
- (d) Investment Company registered under Section 8 of the Investment Company Act,

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 28, 1997

Date

BIOTECHNOLOGY INVESTMENT GROUP, L.L.C.
By: COLLINSON HOWE VENTURE PARTNERS, INC.
Its: Managing Member

By: -----
Jeffrey J. Collinson, President

EDWARD BLECH TRUST

By: -----
Mordechai Jofen, as Sole Trustee

COLLINSON HOWE VENTURE PARTNERS, INC.

By: -----
Jeffrey J. Collinson, President

JEFFREY J. COLLINSON

SCHRODERS INCORPORATED

By: -----
Jeffrey J. Collinson, Its Attorney-in-Fact

SCHRODER VENTURES U.S. TRUST
By: SCHRODER VENTURE MANAGERS LIMITED
Its: Manager

By: -----

SCHRODER VENTURES LIMITED
PARTNERSHIP
By: SCHRODER VENTURES MANAGEMENT L.P.
Its: General Partner
By: SCHRODER VENTURE MANAGERS INC.
Its: General Partner

By: -----

* By: /s/Timothy C. Maguire

Timothy C. Maguire, Attorney-in-Fact

14

CUSIP NO. 015351109

13G

PAGE 14 OF 17

EXHIBIT 1

AGREEMENT

Pursuant to Rule 13d-1(f)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed on behalf of all of the undersigned with respect to the ownership of shares of Common Stock of Alexion Pharmaceuticals, Inc. by any of the undersigned.

This agreement may be executed in any number of counterparts, each of which shall be deemed an original.

EXECUTED as a sealed instrument this 28th day of February, 1997.

BIOTECHNOLOGY INVESTMENT GROUP, L.L.C.
By: COLLINSON HOWE VENTURE PARTNERS, INC.
Its: Managing Member

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson, President

EDWARD BLECH TRUST

By: /s/Mordechai Jofen

Mordechai Jofen, as Sole Trustee

COLLINSON HOWE VENTURE PARTNERS, INC.

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson, President

/s/Jeffrey J. Collinson

JEFFREY J. COLLINSON

SCHRODERS INCORPORATED

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson
Its: Attorney-in-Fact

SCHRODER VENTURES U.S. TRUST
By: SCHRODER VENTURE MANAGERS LIMITED
Its: Manager

By: /s/Peter Everson

Peter Everson

15

CUSIP NO. 015351109

13G

PAGE 15 OF 17

SCHRODER VENTURES LIMITED
PARTNERSHIP
By: SCHRODER VENTURES MANAGEMENT L.P.
Its: General Partner
By: SCHRODER VENTURE MANAGERS INC.
Its: General Partner

By: /s/Peter Everson

Peter Everson

16

CUSIP NO. 015351109

13G

PAGE 16 OF 17

Exhibit 2

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below, and each entity for which an authorized signature appears below, hereby constitutes and appoints Timothy C. Maguire and Anne G. Plimpton, and each of them, each with full power to act without the other, his, her or its, as the case may be, true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself, herself or itself, as the case may be, as an individual or in his, her or its, as the case may be, capacity as a general partner of any partnership or a trustee of any trust, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, all in connection with the beneficial ownership of securities held by the undersigned, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, Inc., granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby

ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney will remain in effect until revoked by an instrument in writing delivered to the aforesaid attorney(s)-in-fact. The undersigned each acknowledge that Timothy C. Maguire and Anne G. Plimpton are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 12th day of February, 1997.

BIOTECHNOLOGY INVESTMENT GROUP, L.L.C.
By: COLLINSON HOWE VENTURE PARTNERS, INC.
Its: Managing Member

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson,
President

EDWARD BLECH TRUST

By: /s/Mordechai Jofen

Mordechai Jofen,
as Sole Trustee

/s/Mordechai Jofen

Mordechai Jofen

COLLINSON HOWE VENTURE PARTNERS, INC.

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson,
President

17

CUSIP NO. 015351109

13G

PAGE 17 OF 17

/s/Jeffrey J. Collinson

Jeffrey J. Collinson

SCHRODERS INCORPORATED

By: /s/Jeffrey J. Collinson

Jeffrey J. Collinson
Its: Attorney-in-Fact

SCHRODER VENTURES LIMITED PARTNERSHIP

By: SCHRODER VENTURES MANAGEMENT L.P.

Its: General Partner

By: SCHRODER VENTURE MANAGERS INC.

Its: General Partner

By: /s/Peter Everson

Peter Everson

SCHRODER VENTURES U.S. TRUST

By: SCHRODER VENTURE MANAGERS LIMITED

Its: Manager

By: /s/Peter Everson

Peter Everson